The Subsidiary Of Sailong Pharmaceutical Has Obtained The Approval Notice For The Marketing Application Of Nicorandil Active Pharmaceutical Ingredient.

Dec 11, 2025

Leave a message

Sailong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") announces the relevant matters as follows: its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co., Ltd., has recently obtained the Approval Notice for the Marketing Application of Chemical Active Pharmaceutical Ingredient for Nicorandil, which was officially issued and approved by the National Medical Products Administration (NMPA).

I. Basic Information of the Active Pharmaceutical Ingredient (API)

Name of the chemical API: Nicorandil

Notice No.: 2024YS01274

Registration No.: Y20230000829

Acceptance No.: CYHS2360684

Registration Standard No. of the chemical API: YBY75392024

Validity Period: 18 months

Packaging Specification: 2kg/bag

Application Item: Marketing application for domestically produced chemical API

Approval Conclusion: In accordance with the Drug Administration Law of the People's Republic of China and relevant regulations, upon review, this product meets the relevant requirements for drug registration and is approved for registration. The quality standard, label and production process shall be implemented in accordance with the attached documents.

Validity Period of the Notice: Until December 10, 2029

II. Other Relevant Information

Preparations containing Nicorandil are mainly indicated for the treatment of angina pectoris.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!